<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267966</url>
  </required_header>
  <id_info>
    <org_study_id>NI 01/13</org_study_id>
    <nct_id>NCT03267966</nct_id>
  </id_info>
  <brief_title>Margin Status After Pancreaticoduodenectomy for Cancer</brief_title>
  <official_title>Margin Status After Pancreaticoduodenectomy for Cancer. Results of a Multicentric Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campus Bio-Medico University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humanitas Hospital, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Silesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Campus Bio-Medico University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates if a standardized method of pathological evaluation of the specimen
      affects the R1 resection rate after Pancreatico-Duodenectomy (PD) for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growing evidence in literature shows that the use of a standardized method of pathological
      evaluation of the specimen determines a significant increase of the R1 resection rate. At the
      moment, no randomized controlled trials have been published on this topic.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R1 resection rate</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate difference in terms of R1 resection rates between study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>impact of minimum clearance definition</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the impact of minimum clear definition on R1 resection rate in both study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological data</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate differences in pathological results (T status, N status, number of blocks, number of lymphnodes, etc) between the two study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oncological results</measure>
    <time_frame>36 months</time_frame>
    <description>To evaluate the correlation between R1 resection and oncological results (local recurrence, overall survival) in the two study groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Ampullary Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized method of pathological evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non standardized method of pathological evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Standardized method of pathological evaluation</intervention_name>
    <description>PD specimen is evaluated according a standardized method of pathological evaluation, that includes: 1) multicolor inking; 2) axial slicing; 3) clearance definition of 1 mm</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pancreaticoduodenectomy for periampullary cancer

        Exclusion Criteria:

          -  diagnosis of neuroendocrine neoplasm;

          -  previous pancreatic surgery;

          -  frozen section of each transection margins not performed or presence of positive
             transection margins without further resection (R1 intraoperative resection);

          -  presence of macroscopic residual tumor (R2 resection).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>August 29, 2017</last_update_submitted>
  <last_update_submitted_qc>August 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campus Bio-Medico University</investigator_affiliation>
    <investigator_full_name>Gennaro Nappo</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>periampullary cancer</keyword>
  <keyword>margin status</keyword>
  <keyword>R1 resection</keyword>
  <keyword>clearance margin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

